Concordance of HER2 and its related molecules between primary and paired liver metastatic sites in gastric cancer.

4108 Background: Trastuzumab is the 1st molecular targeting drug in HER2-positive advanced gastric cancer that has been shown to confer overall survival benefit adding to chemotherapy. In breast cancer it has been already used long time, it is known that there are the discordance of its target; HER2 between primary and metastatic site. Although molecular targeting drugs as Trastuzumab are expected to control the metastatic disease, molecular status is usually evaluated in the primary site because metastatic sites are difficult to biopsy. In this study we attempted to compare HER2 and its related molecular status, which have interaction each together, between primary and paired liver metastatic sites in gastric cancer. Methods: Total 58 consecutive cases with gastric cancer who underwent surgical resection of primary site and synchronous or metachronous liver metastasis were examined. HER2, EGFR, c-MET and IGF-1R status were evaluated by immunohistochemistry(IHC) in primary and paired liver metastasis. HER2 expression by IHC using HercepTest (DAKO) were assessed according to Gastric Cancer Scoring System. On the other molecular expression by IHC, positive expression was defined as 25% or more staining with intensity 2 or 3+. We analyzed the concordance of their expression in both sites. Results: The patient cohort consists predominantly of male (78%), with Lauren’s diffuse (37%) and intestinal tumors (62%). Fifty three percent of cases were synchronous liver metastasis. The positive rate of primary and paired liver metastatic sites were 10.3%, 8.6% in HER2, 1.7%, 5.1% in EGFR, 44.8%, 31.0% in c-MET and 31.0%, 29.3% in IGF-1R. The concordance between primary and paired liver metastatic sites were 91.3%, 93.1%, 75.8%, and 70.6%, respectively. Conclusions: Our data suggested that in HER2 and EGFR the concordance between primary and metastatic site were high, other hands the concordance of c-MET and IGF-1R were relatively low. It might be necessary to rebiopsy to estimate the expression of c-MET and IGF-1R in gastric cancer.

Download Full-text

Alpha-radioimmunotherapy Against Liver Metastasis of HER2-positive Gastric Cancer in a Mouse Model

Journal of Medical Imaging and Radiation Sciences ◽

10.1016/j.jmir.2019.03.010 ◽

2019 ◽

Vol 50 (1) ◽

pp. S3

Author(s):

Sumitaka Hasegawa ◽

Huizi Keiko Li

Keyword(s):

Gastric Cancer ◽

Liver Metastasis ◽

Mouse Model ◽

Her2 Positive

Download Full-text

Complete Response in a Case of Metachronous Liver Metastasis of Gastric Cancer Complicated by Pulmonary Tuberculosis Treated with Hepatic Arterial Infusion Chemotherapy Following Anti-tuberculosis Therapy

The Japanese Journal of Gastroenterological Surgery ◽

10.5833/jjgs.2015.0200 ◽

2016 ◽

Vol 49 (10) ◽

pp. 997-1005

Author(s):

Hiroshi Kubo ◽

Tomomi Kashiwada ◽

Hirokazu Noshiro ◽

Yoshihiko Kitajima

Keyword(s):

Gastric Cancer ◽

Liver Metastasis ◽

Pulmonary Tuberculosis ◽

Hepatic Arterial Infusion ◽

Complete Response ◽

Arterial Infusion ◽

Arterial Infusion Chemotherapy ◽

Infusion Chemotherapy ◽

Metachronous Liver Metastasis ◽

Tuberculosis Therapy

Download Full-text

Efficacy of cytotoxic agents after progression of anti-PD-(L)1 antibody for pretreated metastatic gastric cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.4_suppl.152 ◽

2018 ◽

Vol 36 (4_suppl) ◽

pp. 152-152

Author(s):

Kyoko Kato ◽

Yukiya Narita ◽

Seiichiro Mitani ◽

Kazunori Honda ◽

Toshiki Masuishi ◽

...

Keyword(s):

Gastric Cancer ◽

Univariate Analysis ◽

Patient Characteristics ◽

Metastatic Gastric Cancer ◽

Cytotoxic Agents ◽

Her2 Positive ◽

Period Range ◽

Median Period ◽

Metastatic Sites ◽

Ecog Ps

152 Background: The efficacy of anti-PD-1 antibody for metastatic gastric cancer (mGC) was revealed. In non-small cell lung cancer (NSCLC), it was reported that overall response rate (ORR) in patients (pts) treated with chemotherapy (CTx) after immunotherapy exposure was higher than historical data from the pre-anti-PD-(L)1 era. The purpose of this retrospective study was to evaluate whether CTx improved efficacy outcomes after exposure anti-PD(L)1 antibody in mGC. Methods: We investigated retrospectively clinical characteristics at baseline of mGC pts who received CTx after progression of anti-PD-(L)1 antibody between April 2014 and August 2017. Anti-PD-(L)1 antibody was adapted as third- or later-line therapy. Pts fulfilled following criteria: histologically proven adenocarcinoma; ECOG PS 0-2; adequate organ functions; and received CTx including fluoropyrimidines (FU), platinum, and taxane or irinotecan. We evaluated efficacy outcomes, including ORR, disease control rate (DCR), time to treatment failure (TTF), and overall survival (OS). Results: Out of 40 treated with anti-PD-(L)1 antibody, 15 pts were included. Patient characteristics were as follows: median age (range), 67 (46-83) years; male/female, 13/2; ECOG PS (0/1/2), 5/8/2; HER2 positive, 8; histology (differentiated/undifferentiated), 10/5; metastatic lesions (peritoneum/liver/lung), 4/8/3; number of metastatic sites (1/≥2), 2/13; number of prior CTx regimens (3/4/5), 2/9/4; median period (range) from first line CTx, 30.7 (12.7-68.1) months; and CTx regimens (FU+oxaliplatin/taxane/irinotecan), 10/3/2. ORR, DCR, median TTF, and OS were 33% (95% CI, 15.2-58.3), 87% (95% CI, 62.1-96.3), 3.5 (95% CI, 1.6-4.4) months, and 7.6 (95% CI, 4.4-8.5) months, respectively. There were no predictive and prognostic factors associated with ORR, TTF, and OS on univariate analysis. At the beginning of CTx, 4 pts had immune-related adverse events (irAEs), but these were manageable and no new irAEs appeared during CTx. Conclusions: Our data support further evaluation of the use of CTx after progression of anti-PD-L 1 antibody, even in heavily pretreated mGC pts. Updated results will be presented.

Download Full-text

P-0059 is Radiofrequency Ablation is Effective for Metachronous Liver Metastasis from Gastric Cancer?

Annals of Oncology ◽

10.1016/s0923-7534(20)30266-0 ◽

2012 ◽

Vol 23 ◽

pp. iv47-iv48

Author(s):

Jun-Eul Hwang ◽

Dae-Eun Kim ◽

Shim Hyun-Jeong ◽

Woo-Kyun Bae ◽

Sang-Hee Cho ◽

...

Keyword(s):

Gastric Cancer ◽

Radiofrequency Ablation ◽

Liver Metastasis ◽

Metachronous Liver Metastasis

Download Full-text

Dual Block HER2 Assessment Increased HER2 Immunohistochemistry Positive Rate in Resected Specimens of Gastric Cancer: A Prospective Multicenter Clinical Trial From China

10.21203/rs.3.rs-944694/v1 ◽

2021 ◽

Author(s):

Chen Xu ◽

Miaomiao Sun ◽

Mei Jin ◽

Zengshan Li ◽

Rong Qin ◽

...

Keyword(s):

Gastric Cancer ◽

Clinical Trial ◽

Primary Tumor ◽

Routine Clinical Practice ◽

Histological Evaluation ◽

Multicenter Clinical Trial ◽

Her2 Positive ◽

Positive Rate ◽

Rabbit Monoclonal Antibody ◽

Single Block

Abstract Background Former single center studies indicated that HER2 assessment with two primary tumor blocks (dual block HER2 assessment) could be an efficient and practical approach to overcome the adverse impact of heterogeneity and acquire a HER2 positive rate in gastric cancer (GC). This multicenter prospective clinical trial (NCT 02843412) was launched to verify its value and generality. Methods A total of 3806 participants with primary GCs have been enrolled from 8 hospitals in China. Two primary tumor blocks were selected and recorded as block 1 and block 2 after histological evaluation. An HER2 (4B5) rabbit monoclonal antibody was used for the immunohistochemistry (IHC) analysis. In total patients, HER2 IHC positive (3+) rate with dual block assessment (9.4%) was higher than that with single block assessment (block 1: 7.8%, block 2: 7.8%) (P < 0.001). Compared with single-block assessment, dual-block assessment increased the positive rate by approximate 20%. Similarly, HER2 equivocal (2+) rate was increased in dual block assessment (25.8%), which was higher than that in single block assessment (block 1: 20.3%, block 2: 20.9%) (P < 0.001). Conversely, dual block assessment demonstrated a lower HER2 negative (0/1+) rate (64.8%) than single block assessment (block1: 71.9%, block 2: 71.3%) (P < 0.001). These findings were also confirmed in individual hospitals. Conclusions Dual block HER2 assessment effectively increased HER2 IHC positive rate in resected specimens of GC. We recommended dual block HER2 assessment be promoted in routine clinical practice in GC.

Download Full-text